The global peptide API market is driven by the increasing prevalence of chronic diseases, including cancer, diabetes, and cardiovascular disorders, which are among the leading causes of morbidity and mortality worldwide. According to the International Diabetes Federation (IDF), approximately 537 billion adults aged 20-79 were living with diabetes in 2021, and this number is projected to rise to 783 billion by 2045, creating significant demand for peptide-based therapeutic APIs like glucagon-like peptide-1 (GLP-1) analogs. Additionally, the World Health Organization (WHO) reports that nearly 10 billion deaths in 2020 were attributed to cancer, underlining the need for innovative peptide-based anticancer drugs. The increasing adoption of peptides in targeted therapies due to their high specificity and safety profile further accelerates their application in addressing these rising healthcare burdens.
